Please use this identifier to cite or link to this item:
|Title:||Polypharmacology of dopamine receptor ligands||Authors:||Butini, S
|Keywords:||Bivalent ligands; Designed multiple ligands; Dopamine; Drug addiction; Dual ligands; GPCR; Multi-targeting; Multifunctional ligands; Multiple targeting; Parkinson’s disease; Receptor subtypes; Schizophrenia||Issue Date:||2016||Project:||None||Journal:||PROGRESS IN NEUROBIOLOGY||Abstract:||
Most neurological diseases have a multifactorial nature and the number of molecular mechanisms discovered as underpinning these diseases is continuously evolving. The old concept of developing selective agents for a single target does not fit with the medical need of most neurological diseases. The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases. Dopamine and its five receptor subtypes are intimately involved in numerous neurological disorders. Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels. For brain disorders like Parkinsońs disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy. The concept of designed multiple ligands and polypharmacology, which perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular.
|Appears in Collections:||Publications|
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.